Preclinical testing alternatives

SINTEF ranks mRNA nanoparticles by immune uptake in fresh human donor blood

Ninety percent of drug candidates that reach human trials are never approved. A Norwegian group argues some of that triage belongs in donor blood, where nanoparticles meet the plasma proteins and immune cells that settle their fate.